Literature DB >> 19625334

Extensive vasogenic edema of anti-aquaporin-4 antibody-related brain lesions.

T Matsushita1, N Isobe, T Matsuoka, T Ishizu, Y Kawano, T Yoshiura, Y Ohyagi, J Kira.   

Abstract

OBJECTIVE: Using neuroimaging, we analyzed the nature of extensive brain lesions in five anti-aquaporin-4 (AQP4) antibody-positive patients with neuromyelitis optica spectrum disorders.
RESULTS: Extensive brain lesions involved white matter in three, and basal ganglia and corpus callosum in one each. Four patients showed high diffusivity on apparent diffusion coefficient maps and three demonstrated increased choline/creatine ratios and decreased N-acetyl-aspartate/creatine ratios on (1)H-magnetic resonance spectroscopy. These findings suggested that the lesions were vasogenic edema associated with inflammation. Unusual brain symptoms associated with such lesions included recurrent limbic encephalitis, parkinsonism, and coma.
CONCLUSION: Anti-AQP4 antibody is considered to be associated with the neuroimaging appearances of vasogenic edema.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19625334     DOI: 10.1177/1352458509106613

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

Review 1.  Brain MRI in neuromyelitis optica: what is its role?

Authors:  Wei Qiu; Allan G Kermode
Journal:  Curr Neurol Neurosci Rep       Date:  2011-12       Impact factor: 5.081

2.  Devastating aquaporin-4 and HTLV-1-associated necrotizing encephalopathy.

Authors:  Mkael Symmonds; Niranjanan Nirmalananthan; Graham P Taylor; Leslie R Bridges; Frederick Schon
Journal:  J Neurol       Date:  2012-08-24       Impact factor: 4.849

3.  Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis.

Authors:  E Bulut; J Karakaya; S Salama; M Levy; T A G M Huisman; I Izbudak
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-07       Impact factor: 3.825

Review 4.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

Review 5.  MRI characteristics of neuromyelitis optica spectrum disorder: an international update.

Authors:  Ho Jin Kim; Friedemann Paul; Marco A Lana-Peixoto; Silvia Tenembaum; Nasrin Asgari; Jacqueline Palace; Eric C Klawiter; Douglas K Sato; Jérôme de Seze; Jens Wuerfel; Brenda L Banwell; Pablo Villoslada; Albert Saiz; Kazuo Fujihara; Su-Hyun Kim
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

6.  Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.

Authors:  Yeliz Pekcevik; Charles H Mitchell; Maureen A Mealy; Gunes Orman; In H Lee; Scott D Newsome; Carol B Thompson; Carlos A Pardo; Peter A Calabresi; Michael Levy; Izlem Izbudak
Journal:  Mult Scler       Date:  2015-07-24       Impact factor: 6.312

Review 7.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  Nat Rev Neurol       Date:  2010-07       Impact factor: 42.937

Review 8.  What do we know about brain contrast enhancement patterns in neuromyelitis optica?

Authors:  Yeliz Pekcevik; Gunes Orman; In Ho Lee; Maureen A Mealy; Michael Levy; Izlem Izbudak
Journal:  Clin Imaging       Date:  2015-07-26       Impact factor: 1.605

9.  Recurrent Longitudinally Extensive Myelitis and Aquaporin-4 Seronegativity - The Expanding Spectrum of Neuromyelitis Optica.

Authors:  Ravi Anadure; Coimbatore Sivasubramanian Narayanan; Govindaraj Varadraj
Journal:  J Clin Diagn Res       Date:  2017-04-01

10.  Aggravated inflammation and increased expression of cysteinyl leukotriene receptors in the brain after focal cerebral ischemia in AQP4-deficient mice.

Authors:  Wen-Zhen Shi; Chun-Zhen Zhao; Bing Zhao; Qiao-Juan Shi; Li-Hui Zhang; Yan-Fang Wang; San-Hua Fang; Yun-Bi Lu; Wei-Ping Zhang; Er-Qing Wei
Journal:  Neurosci Bull       Date:  2012-11-06       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.